Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy of Neurology ...

Sunshine Cruz recently revealed that she’s battling an autoimmune disease called myasthenia gravis. In an Instagram post, the ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Nkarta restructures to extend its cash runway into 2029, with upcoming NKX019 clinical data readouts in H2 2025. Analysts ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat ...